Study to Evaluate the Leish-111F + MPL-SE Vaccine in the Treatment of Mucosal Leishmaniasis

This study has been completed.

Sponsor:

Collaborator:

Bill and Melinda Gates Foundation

Information provided by:

Infectious Disease Research Institute

ClinicalTrials.gov Identifier:

NCT00111514

First received: May 20, 2005

Last updated: February 13, 2007

Last verified: February 2007

History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study has been completed.
Estimated Study Completion Date:	May 2006
Estimated Primary Completion Date:	No date given

No publications provided by Infectious Disease Research Institute

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Llanos-Cuentas A, Calderón W, Cruz M, Ashman JA, Alves FP, Coler RN, Bogatzki LY, Bertholet S, Laughlin EM, Kahn SJ, Beckmann AM, Cowgill KD, Reed SG, Piazza FM. A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine when used in combination with sodium stibogluconate for the treatment of mucosal leishmaniasis. Vaccine. 2010 Oct 28;28(46):7427-35. Epub 2010 Sep 17.

To Top